Showing 5661-5670 of 7547 results for "".
- Severe Psoriasis Increases Risk for Heart Diseasehttps://practicaldermatology.com/news/severe-psoriasis-increases-risk-for-heart-disease/2462013/Researchers have found further evidence that patients with severe psoriasis are at higher risk for cardiovascular disease. In this study, a total of 503 patients with psoriasis, and without clinical cardiovascular disease, underwent transthoracic Doppler echocardiography to evaluate cor
- PFAS Exposure Linked to Melanoma in Womenhttps://practicaldermatology.com/news/pfas-exposure-linked-to-melanoma-in-women/2462011/Exposure to PFAS (per- and poly-fluoroalkyl substances) and phenols may be linked to diagnoses of melanoma and other cancers, new research suggests. Women who reported higher levels of exposure to PFDE, a long-chained PFAS compound, had double the odds of a previous melanoma diagnosis;
- Study: AD Ups Risk for IBDhttps://practicaldermatology.com/news/study-ad-ups-risk-for-ibd/2462009/Adults with atopic dermatitis (AD) have a 34% increased risk of developing new-onset inflammatory bowel disease (IBD) compared with individuals who do not have the skin condition, and children have a 44% increased risk, according to a new study from the P
- One to Watch: Nektar Therapeutics' Rezpegaldesleukin Shows Promise in Phase 1b AD Studyhttps://practicaldermatology.com/news/one-to-watch-nektar-therapeutics-rezpegaldesleukin-shows-promise-in-phase-1b-ad-study/2462000/Nektar Therapeutics’ rezpegaldesleukin met several clinical efficacy endpoints with statistically significance, including Body Surface Area (BSA), Dermatology Life (DLQI), and Patient-Oriented Eczema Measure (POEM) in addition to reported efficacy for Eczema Area and Severity
- Innovation in Action: A Newly Developed Anti-bacterial Silver Gel May Best Other Silver-based Drugshttps://practicaldermatology.com/news/innovation-in-action-a-newly-developed-anti-bacterial-silver-gel-may-best-other-silver-based-drugs/2461999/A new anti-bacterial gel based on silver and sulfur-containing amino acids may be one hundred times more effective than other silver-based antibacterials, according to research in the Journal of Material
- ‘SUNucate’ Laws Do Increase Interest in Sun Protection, Youth Sunscreen Usehttps://practicaldermatology.com/news/sunucate-laws-do-increase-interest-in-sun-protection-youth-sunscreen-use/2461998/States that enacted SUNUCATE laws permitting children to carry and apply sunscreen at school experienced an increased interest in sun protection and a higher rate of sunscreen use among adolescents, according to new research by a University of Massachusetts Amherst resource economist.
- New Surgical Technique Offers Hope to Folliculitis Decalvans Patientshttps://practicaldermatology.com/news/experimental-surgical-technique-offers-hope-to-folliculitis-decalvans-patients/2461997/The lack of long-term solutions in the challenging treatment of folliculitis decalvans (FD) led Sanusi Umar MD, and colleagues from Dr. U Hair and Skin Clinic to develop and patent a novel device that holds potential for sustained FD remission.
- Biosimilar News: Samsung Bioepis, Sandoz to Develop SB17, a Proposed Stelara Biosimilar to Stelarahttps://practicaldermatology.com/news/biosimilar-news-samsung-bioepis-sandoz-to-develop-sb17-a-proposed-stelara-biosimilar-to-stelara/2461991/Samsung Bioepis Co., Ltd. has entered into a commercialization agreement with Sandoz for SB17, a proposed biosimilar to Stelara (ustekinumab). Samsung Bioepis will be responsible for development, regulatory registration and manufacture and supply of the product in t
- Study Sheds Light on Why Wounds Heal Poorly in People With Diabeteshttps://practicaldermatology.com/news/study-sheds-light-on-why-wounds-heal-poorly-in-people-with-diabetes/2461989/When exosomes are defective in diabetic patients, they can drive inflammation and impair healing of wounds, according to a new Nano Today study led by University of Pittsburgh and UPMC researchers
- Tarsus Rolls Out XDEMVY for Demodex Blepharitishttps://practicaldermatology.com/news/tarsus-rolls-out-xdemvy-for-demodex-blepharitis/2461985/Tarsus Pharmaceuticals, Inc. is rolling out XDEMVY, the First and Only US Food and Drug Administration-approved treatment for Demodex blepharitis. XDEMVY is now available at pharmacies nationwide for prescription. Bobak Azamian, MD, PhD, Chief Executive Officer, and Chairman, ran